Asthma control and clinical remission in severe eosinophilic asthma (SEA) after 2 years of benralizumab treatment: prospective real-world data from XALOC-2

Background : Prospective long-term real-world data on the effectiveness of benralizumab on asthma symptom control in patients (pts) with SEA are lacking. Aim: Examine real-world effectiveness of benralizumab over 112 weeks (Wks). Methods: XALOC-2 comprises prospective, real-world studies of pts with SEA treated with benralizumab in Belgium, Canada, Germany and Switzerland. This 112 Wk integrated analysis assessed Asthma Control Questionnaire (ACQ) scores, annualised asthma exacerbation rate (AAER) and 3-component clinical remission (no exacerbations, no maintenance oral corticosteroid use, asthma symptom control [ACQ